A prospective randomized trial on abacavir/lamivudine plus darunavir/ritonavir or raltegravir in HIV-positive drug-naïve patients with CD4<200 cells/uL (the PRADAR study).
Mussini C, Roncaglia E, Borghi V, Rusconi S, Nozza S, Cattelan AM, Segala D, Bonfanti P, Di Biagio A, Barchi E, Focà E, Degli Antoni A, Bonora S, Francisci D, Limonta S, Antinori A, D'Ettorre G, Maggiolo F.
Mussini C, et al.
PLoS One. 2019 Sep 27;14(9):e0222650. doi: 10.1371/journal.pone.0222650. eCollection 2019.
PLoS One. 2019.
PMID: 31560700
Free PMC article.
Clinical Trial.